The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types ...
Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback